Core Viewpoint - A securities class action lawsuit has been filed against TransMedics Group, Inc. for allegedly misleading investors and failing to disclose critical issues during the Class Period from February 28, 2023, to January 10, 2025 [1][3]. Company Overview - TransMedics Group, Inc. is a medical technology company based in Andover, Massachusetts, specializing in transplant services, including its Organ Care System (OCS), which is a portable organ preservation system [2]. Allegations - The lawsuit claims that TransMedics engaged in unethical practices, including using kickbacks, fraudulent overbilling, and coercive tactics to generate business and revenue [3]. - It is also alleged that the company concealed safety issues and lacked proper safety oversight within its operations [3]. Impact of Revelations - On February 21, 2024, U.S. Rep. Paul Gosar accused TransMedics of misappropriating corporate resources, leading to a stock price drop of $2.18 per share (2.5%) to close at $84.81 on February 22, 2024 [4]. - Following a report from Scorpion Capital on January 10, 2025, which accused TransMedics of overbilling hospitals and providing rejected organs, the stock fell by $3.74 per share (5%) to close at $68.81, and then further declined by $4.76 per share (6.9%) to close at $64.05 on January 13, 2025 [5].

NEW YORK, April 01, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in GSK plc ("GSK" or the "Company") (NYSE: GSK) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of GSK investors who were adversely affected by alleged securities fraud between February 5, 2020 and August 14, 2022. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/gsk-lawsuit-submission-form?prid=139926&wire= ...

Kessler Topaz Meltzer & Check, LLP encourages Maravai investors who have suffered significant losses to contact the firm directly to acquire more information. CLICK HERE TO SIGN UP FOR THE CASE OR GO TO: https://www.ktmc.com/new-cases/maravai- lifesciences-holdings-inc?utm_source=PR&utm_medium=link&utm_campaign=mrvi&mktm=r ABOUT KESSLER TOPAZ MELTZER & CHECK, LLP: RADNOR, Pa., March 31, 2025 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities ...

The Skyworks class action lawsuit further alleges that on February 5, 2025, Skyworks announced its financial results for the first quarter of fiscal year 2025 and provided lower-than anticipated revenue guidance for the second quarter of fiscal year 2025, attributing the results and low guidance to a "competitive landscape" that had "intensified" in recent years. On this news, the price of Skyworks stock fell more than 24%, according to the complaint. THE LEAD PLAINTIFF PROCESS: The Private Securities Litig ...

You can also contact attorneys J.C. Sanchez or Jennifer N. Caringal of Robbins Geller by calling 800/449- 4900 or via e-mail at info@rgrdlaw.com. https://www.rgrdlaw.com/cases-transmedics-group-inc-class-action-lawsuit-tmdx.html If you suffered substantial losses and wish to serve as lead plaintiff of the TransMedics class action lawsuit, please provide your information here: CASE ALLEGATIONS: TransMedics is a commercial-stage medical technology company that engages in transforming organ transplant therapy ...

Core Viewpoint - ModivCare, Inc. is facing a class action lawsuit alleging violations of the Securities Exchange Act of 1934, with claims related to misleading statements and insufficient liquidity impacting the company's financial performance [1][2]. Group 1: Allegations and Financial Impact - The lawsuit claims that ModivCare made false or misleading statements regarding contract renegotiations and pricing accommodations, which negatively affected the company's adjusted EBITDA [2]. - It is alleged that ModivCare had insufficient liquidity during the class period, further exacerbating its financial challenges [2]. Group 2: Legal Process and Participation - The Private Securities Litigation Reform Act of 1995 allows any investor who purchased ModivCare securities during the class period to seek appointment as lead plaintiff in the lawsuit [3]. - The lead plaintiff is expected to have the greatest financial interest in the case and will represent the interests of all class members [3]. Group 3: Law Firm Background - Robbins Geller Rudman & Dowd LLP is a prominent law firm specializing in securities fraud cases, having secured over $6.6 billion for investors in related class action cases [4]. - The firm has been recognized for its significant recoveries, including the largest securities class action recovery in history amounting to $7.2 billion in the Enron case [4].

PHILADELPHIA, March 25, 2025 (GLOBE NEWSWIRE) -- Berger Montague PC advises investors that a securities class action lawsuit has been filed against Fluence Energy, Inc. (“Fluence” or the “Company”) (NASDAQ: FLNC) on behalf of purchasers of Fluence securities between November 29, 2023 through February 10, 2025, inclusive (the “Class Period”). Investor Deadline: Investors who purchased or acquired Fluence securities during the Class Period may, no later than MAY 12, 2025, seek to be appointed as a lead plaint ...

PHILADELPHIA, March 24, 2025 (GLOBE NEWSWIRE) -- Berger Montague PC advises investors that a securities class action lawsuit has been filed against Arconic Corporation (“Arconic” or the “Company”) (NYSE: ARNC) on behalf of sellers of Arconic securities between April 19, 2022 through May 3, 2023, inclusive (the “Class Period”). Investor Deadline: Investors who sold ARCONIC securities during the Class Period may, no later than MARCH 31, 2025, seek to be appointed as a lead plaintiff representative of the clas ...

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Elastic N.V. regarding a class action lawsuit due to alleged misleading statements and operational disruptions affecting sales during FY 2025 [1]. Group 1: Allegations and Class Period - The class period for the allegations is from May 31, 2024, to August 29, 2024 [1]. - Allegations include that Elastic made significant changes to its sales operations, particularly affecting customer segments in the Americas, which disrupted sales operations in the first quarter of FY 2025 [1]. - It is claimed that these changes led to an overstatement of the stability of Elastic's sales operations and that the company was unlikely to meet its previously issued revenue guidance for FY 2025 [1]. Group 2: Next Steps for Shareholders - Shareholders are encouraged to register for the class action by April 14, 2025, to potentially be appointed as lead plaintiffs [2]. - Once registered, shareholders will receive updates through a portfolio monitoring software regarding the case's status [2]. - Participation in the case incurs no cost or obligation for the shareholders [2]. Group 3: Law Firm's Mission - The Gross Law Firm aims to protect investors' rights who have suffered from deceit, fraud, and illegal business practices [3]. - The firm is committed to ensuring companies adhere to responsible business practices and seeks recovery for investors affected by misleading statements that inflated stock prices [3].

Core Viewpoint - A class action lawsuit has been filed against TFI International Inc. and certain senior executives for alleged violations of federal securities laws during the class period from April 26, 2024, to February 19, 2025 [1][5]. Group 1: Company Overview - TFI International Inc. is a transportation and logistics company operating in the United States and Canada, with four segments: Package & Courier, Less-than-Truckload (LTL), Truckload, and Logistics [4]. - Approximately 43% of TFI's revenue is derived from its LTL segment, which includes TForce Freight, acquired from United Parcel Service, Inc. in April 2021 [4]. Group 2: Allegations and Issues - The lawsuit alleges that TFI's executives made materially false and misleading statements and failed to disclose adverse facts about the company's business and operations [5]. - Specific issues cited include the loss of small and medium-sized customers, declining TForce Freight revenue, struggles in cost management, and negative impacts on LTL segment profitability [5][6]. Group 3: Impact of Disclosure - The truth about TFI's challenges was revealed on February 19, 2025, during a conference call discussing the fourth quarter and full year 2024 financial results, where executives acknowledged significant customer losses and cost management issues [6][7]. - Following this disclosure, TFI's stock price fell by $26.13 per share, or 20.5%, closing at $101.48 per share on February 20, 2025 [7].